Prognostic value of fibrinogen and D-dimer-fibrinogen ratio in resectable gastrointestinal stromal tumors

Table 2 Univariate analysis of association between clinicopathologic features and prognosis in gastrointestinal stromal tumor patients

Characteristic	Number	3-yr RFS (%)	5-yr RFS (%)	95%CI	P value
Gender
Male	91	80	75	61.170-72.86	0.498
Female	79	90	80	56.828-65.996
Age (yr)
< 61	78	85	81	58.018-66.650	0.406
≥ 61	92	83	78	61.508-73.445
NIH risk category
Very low, low	83	97	95	73.805-80.329	< 0.01
Intermediate, high	87	80	65	50.488-62.245
Tumor size (cm)
≤ 5	97	95	95	75.130-80.262	< 0.01
> 5	73	63	55	49.388-63.256
Tumor location
Gastric	122	92	85	67.968-76.637	0.001
Extragastric	48	76	55	42.703-56.229
FIB (g/L)
< 3.24	95	95	95	75.248-80.253	< 0.01
≥ 3.24	75	65	50	48.878-62.958
D-dimer (mg/L)
< 1.24	118	95	88	70.09-88.603	< 0.01
≥ 1.24	52	65	55	46.163-62.647
DFR
< 0.354	126	95	85	70.237-78.220	< 0.01
≥ 0.354	44	70	50	43.262-61.237
PLT (× 109/L)
< 197.5	81	92	85	68.060-78.540	0.014
≥ 197.5	89	76	68	55.307-67.619
Mitotic index
≤ 5/50 HPFs	125	95	90	70.431-77.808	< 0.01
> 5/50 HPFs	45	65	35	39.663-55.513
Adjuvant imatinib1
Yes	48	70	55	48.468-64.287	0.940
No	39	75	55	41.127-64.055

¹Intermediate and high risk gastrointestinal stromal tumor patients. GIST: Gastrointestinal stromal tumor; NIH: National Institutes of Health; FIB: Fibrinogen; RFS: Recurrence-free survival; DFR: D-dimer to FIB ratio (D-dimer/FIB); PLT: Platelet count.